Recombinant Human LAG-3 Fc Chimera Protein, CF | R&D Systems 2319-L3-050 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human LAG-3 Fc Chimera Protein, CF

catalog :

2319-L3-050

quantity :

50 ug

price :

443 USD

citations: 6

Reference
Manna L, Rapuano Lembo R, Yoshioka A, Nakamura K, Passariello M, De Lorenzo C. A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies. Cancers (Basel). 2023;15: pubmed publisher
Pedersen J, Hansen A, Skej xf8 C, Juul Madsen K, Junker P, H xf8 rslev Petersen K, et al. Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis. Arthritis Res Ther. 2023;25:97 pubmed publisher
Fittje P, H x153 lzemer A, Garcia Beltran W, Vollmers S, Niehrs A, Hagemann K, et al. HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells. PLoS Pathog. 2022;18:e1010572 pubmed publisher
Edwards C, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, et al. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br J Cancer. 2021;: pubmed publisher
Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker J, et al. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J Immunol. 2017;199:604-612 pubmed publisher
Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol. 2015;194:3873-82 pubmed publisher

product information

master code :

2319-L3

SKU :

2319-L3-050

product name :

Recombinant Human LAG-3 Fc Chimera Protein, CF

unit size :

50 ug

description :

The Recombinant Human LAG-3 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human LAG-3 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

LAG-3

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Human

observed molecular weight :

75-90 kDa, under reducing conditions.

theoretical molecular weight :

72.7 kDa (monomer)

gene symbol :

LAG3

details of functionality :

Measured by its ability to induce TNF-alpha secretion by JAWSII mouse immature dendritic cells. The ED50 for this effect is 1-4 ╡g/mL.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

P18627

applications :

Bioactivity

source long :

Mouse myeloma cell line, NS0-derived human LAG-3 protein Human LAG-3 (Leu23-Leu450) Accession # P18627 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus

source short :

NS0

USD :

443 USD

alt names :

CD223, CD223 antigen, LAG3, LAG-3, lymphocyte activating 3, lymphocyte activation gene 3 protein, lymphocyte-activation gene 3, Secreted lymphocyte activation gene 3 protein, sLAG-3

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, <= -20 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, <= -20 ░C under sterile conditions after reconstitution.